US patent sought for obesity susceptibility test:
This article was originally published in Clinica
Executive Summary
GeneLink has filed a US patent application covering its non-invasive genetic test for assessing an individual's susceptibility to obesity. The test, which measures single-nucleotide polymorphisms in several genes, could help nutritional companies and those involved in medical, health and weight loss management offer an earlier and improved approach to obesity management, claims the Margate, New Jersey firm. Sample collection involves mailing saliva swabs to a testing laboratory. John De Phillipo, GeneLink's, chairman and CEO says the firm has already "received an overwhelming response from major weight loss and nutritional companies seeking distribution".
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.